Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAZIT: Pazopanib with Irinotecan and Temozolomide in Sarcoma
NCT03139331Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pazopanib in sarcoma, sponsored by University of California, San Francisco. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose-Limiting Toxicities at 3 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
pazopanib
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT03139331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139331.